Differential effects of chronic clorgyline and amfonelic acid on desensitization of striatal dopamine receptors.
Chronic treatment of rats with the MAOI clorgyline significantly reduced the density (Bmax) of cortical beta-adrenergic receptors but did not alter either the Bmax or dissociation constant (Kd) of 3H-spiperone binding to striatal DA receptors. Clorgyline co-treatment also did not significantly affect either behavioral supersensitivity to apomorphine or the increase in 3H-spiperone binding induced by chronic haloperidol. In contrast, repeated treatment with the DA uptake inhibitor amfonelic acid elicited behavioral subsensitivity and reduced striatal 3H-spiperone binding. Furthermore, amfonelic acid co-treatment prevented haloperidol-induced behavioral and receptor binding changes. The possible relevance of these findings in relation to drug choice in clinical trials of receptor sensitivity modification are discussed.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D002540:Cerebral Cortex / Q000378:metabolism; D003010:Clorgyline / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004082:Dihydroalprenolol / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D008996:Monoamine Oxidase Inhibitors; D009268:Nalidixic Acid / Q000031:analogs & derivatives; D009287:Naphthyridines / Q000494:pharmacology*; D011437:Propylamines / Q000494:pharmacology*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000378:metabolism; D013134:Spiperone / Q000378:metabolism; D013892:Thioxanthenes / Q000378:metabolism
D008996:Monoamine Oxidase Inhibitors; D009287:Naphthyridines; D011437:Propylamines; D011954:Receptors, Dopamine; D013892:Thioxanthenes; D009268:Nalidixic Acid; D013134:Spiperone; D004082:Dihydroalprenolol; C015448:piflutixol; D006220:Haloperidol; D003010:Clorgyline; D001058:Apomorphine; C006486:amfonelic acid